Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.51 |
| ▸ | CTSS | P25774 | 5/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1312767 | 1.00 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL999110 | 1.00 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL16710007 | 1.00 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL1312765 | 1.00 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL708582 | 1.00 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL693616 | 1.00 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL1311851 | 1.00 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL23794778 | 0.89 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL30718547 | 0.89 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL23794776 | 0.89 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242572-A1 | a-CARBONYL ALKENYL ESTER PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JIANGXI NORMAL UNIVERSITY (CN) | 2023-08-03 | — | — | US | claimed |
| CN-115252806-A | Preparation method of nano-drug carrier G5-R with high-efficiency tumor penetration capacity | 浙江大学杭州国际科创中心 | 2022-11-01 | — | — | CN | claimed |
| EP-4043447-B1 | HALOGENATED TETRACYCLIC TRITERPENE DERIVATIVE, PREPARATION AND APPLICATION THEREOF | SHANGHAI QINGDONG BIOTECHNOLOGY CO LTD (CN) | 2026-01-21 | — | — | EP | disclosed |
| US-20260014146-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250304603-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250110407-A1 | SEMICONDUCTOR SUBSTRATE MANUFACTURING METHOD, AND RESIST BASE FILM FORMING COMPOSITION | JSR CORPORATION (JP) | 2025-04-03 | — | — | US | disclosed |
| US-20250002495-A1 | SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME | TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) | 2025-01-02 | — | — | US | disclosed |
| US-12157736-B2 | Spiro-lactam NMDA modulators and methods of using same | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2024-12-03 | — | — | US | disclosed |
| CN-118930602-A | Method for performing terminal allylation modification on natural amino acid or polypeptide | 南京工业大学 | 2024-11-12 | — | — | CN | disclosed |
| US-12084444-B2 | Spiro-lactam NMDA modulators and methods of using same | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) | 2024-09-10 | — | — | US | disclosed |
| US-20240294489-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | CAPTOR THERAPEUTICS S.A. (PL) | 2024-09-05 | — | — | US | disclosed |
| US-4833076-A | ANTITUMOR AGENTS | BRISTOL-MYERS COMPANY (US) | 1989-05-23 | — | — | US | disclosed |
| US-4808579-A | 3-(2-(2-AMINO-4-THIAZOLYL))-2-METHOXYIMINOACETYLAMINO-2-OXO-1-AZETIDINYLIMINOACETIC ACID | AMERICAN CYANAMID COMPANY (US) | 1989-02-28 | — | — | US | disclosed |
| US-4789731-A | Semi-synthetic peptide antibiotics | BRISTOL-MYERS COMPANY (US) | 1988-12-06 | — | — | US | disclosed |
| US-4742047-A | ANTITUMOR | BRISTOL-MYERS COMPANY (US) | 1988-05-03 | — | — | US | disclosed |
| US-4692510-A | ANTIBIOTICS, ANTITUMOR AGENTS | BRISTOL-MYERS COMPANY (US) | 1987-09-08 | — | — | US | disclosed |
| US-4681937-A | 3-acylamino-2-oxo-1-azetidinyl esters of phosphonic acids, phosphoric acid and phosphoric acid esters | E. R. SQUIBB & SONS, INC. (US) | 1987-07-21 | — | — | US | disclosed |
| US-4551276-A | 2-Oxoazetidin-1-yloxymethyl sulfonic acid and analogs | E. R. SQUIBB & SONS, INC. (US) | 1985-11-05 | — | — | US | disclosed |
| US-4382142-A | ANTITUMOR AND ANTICARCINOGENIC AGENTS; LEUKEMIA | KOWA CO., LTD. (JP) | 1983-05-03 | — | — | US | disclosed |
| US-4013565-A | MEMBRANES | RHONE-POULENC S.A. (FR) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294489-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | MMP2, PSME2, PSME1 | CTSK 683/4885CTSS 636/4885CA1 3278/4885 |
| US-20250304603-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | CTSK 3925/4885CTSS 3911/4885CA1 3605/4885 |
| US-20230242572-A1 | a-CARBONYL ALKENYL ESTER PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ACSL1, ACSL4, WEE1 | CTSK 2595/4885CTSS 1913/4885CA1 1928/4885 |
| US-12084444-B2 | Spiro-lactam NMDA modulators and methods of using same | GRIN1, GRIN2A, GRIN2C | CTSK 4131/4885CTSS 4130/4885CA1 1579/4885 |
| US-20250002495-A1 | SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME | GRIN1, GRIN2A, GRIN2C | CTSK 4131/4885CTSS 4130/4885CA1 1579/4885 |
| US-12157736-B2 | Spiro-lactam NMDA modulators and methods of using same | GRIN1, GRIN2A, GRIN2C | CTSK 4131/4885CTSS 4130/4885CA1 1579/4885 |
| US-20260014146-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK1 | CTSK 4394/4885CTSS 3999/4885CA1 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.